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ABSTRACT 
In the last years, microRNAs (miRNA) have emerged as new molecular players involved in 
carcinogenesis. Deregulation of miRNAs expression has been shown in different human cancer 
but the molecular mechanism underlying the alteration of miRNA expression is unknown. To 
identify tumor-supressor miRNAs silenced through aberrant epigenetic events in colorectal 
cancer (CRC), we used a sequential approach. We first identified 5 miRNAs down-regulated in 
colorectal cancer patient samples and located around/on a CpG island. Treatment with a DNA 
methyltransferase inhibitor and a HDAC inhibitor restored expression of 3 of the 5 microRNAs 
(hsa-miR-9, hsa-miR-129 and hsa-miR-137) in 3 CRC cell lines. Expression of hsa-miR-9 was 
inversely correlated with methylation of their promoter regions as measure by MSP and 
bisulphate sequencing. Further, methylation of the hsa-miR-9-1, hsa-miR-129-2 and hsa-miR-
137 CpG islands were frequently observed in CRC cell lines and in primary CRC tumors, but not 
in normal colonic mucosa. Finally, methylation of hsa-miR-9-1 was associated with the presence 
of lymph node metastasis. In summary, our results aid in the understanding of miRNA gene 
regulation showing that aberrant DNA methylation and histone modifications work together to 
induce silencing of miRNAs in CRC.  
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INTRODUCTION 
MicroRNAs (miRNAs) are 19- to 25-nt non coding RNAs that are cleaved from 70- to 100-nt 
hairpin-shaped precursors 1. They can regulate gene expression inducing direct mRNA 
degradation or translational inhibition 2. miRNAs are expressed in a tissue-specific manner and 
represent  crucial factors in the regulation of different pathways involved in development, cell 
differentiation, proliferation and apoptosis 3-6. Moreover, abnormal regulation of miRNA 
expression may contribute to the development of human cancer 7-10. Interestingly, down-
regulation of  miRNAs has been demonstrated in tumors in comparison with normal tissue 11, 
suggesting that some miRNAs may behave as putative tumor suppressor genes 12, 13. However, 
although the biological importance of miRNA is becoming increasingly apparent, the molecular 
mechanism underlying regulation of miRNA expression in cancer is not completely understood. 
Specific transcriptional regulation, epigenetic mechanisms including methylation and histone 
deacetylation, gene mutations affecting proteins involved in the processing and maturation of 
microRNAs, or regulation of miRNA stability include some of the mechanism involved in the 
regulation of microRNA expression 14-16. 
 
While methylation of CpG dinucleotides in the promoter region of genes is an important 
mechanism of gene regulation, aberrant hypermethylation of tumor suppressor genes plays a 
significant role in tumor development 17. In fact down-regulation of tumor suppressor genes in 
human cancer has been tightly linked to the presence of CpG island promoter hypermethylation 
18, 19
 and establishes epigenetic regulation as a key mechanism in tumorigenesis. Interestingly, 
recent studies indicate that microRNA expression may be regulated by different epigenetic 
mechanism including abnormal methylation of the promoter regions or histone modifications 20, 
21
. 
 
We and others have recently demonstrated that expression of microRNAs is down-regulated in 
CRC 22, 9 and two different studies 23, 24, comparing the miRNA expression profile of the parental 
HTC116 cell line and the  DNA methyltransferase 1 and 3b (DNMT1 and DNMT3b) double 
knockout cell line suggest that DNA hypermethylation contributes to the transcriptional down-
regulation of microRNAs in CRC.  
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To explore the role of epigenetic mechanisms in the down-regulation of miRNAs in CRC we 
examined the presence of DNA methylation and histone modifications-associated silencing of 
miRNAs and observed that abnormal hypermethylation of the promoters of hsa-miR-9, hsa-miR-
129 and hsa-miR-137 is associated with reduced expression in CRC tissues but rare in normal 
tissue. Our results suggest that DNA hypermethylation and histone modifications contribute to 
the transcriptional down-regulation of miRNAs and may participate in human colorectal 
tumorigenesis. 
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MATERIAL AND METHODS 
Human cancer cell lines and primary tumor samples  
CRC derived cell lines were obtained from the American Type Culture Collection (Rockville, MD, 
USA) and were grown according to the supplier´s instructions. Matched sets of primary colon 
tumors (n=50) and adjacent normal tissues (n=50) were obtained at the time of clinically 
indicated procedures. Total DNA and RNA were isolated from CRC cells and primary tissues by 
Trizol (Invitrogen, San Diego, CA, USA) extraction according to the manufacturer's instructions. 
 
Drug treatment 
CRC derived cell lines were seeded at a concentration of 5x105 cells per 100 mm dish 24 hr 
prior to treatment with 5-Aza-2’-deoxycytidine (AZA: 1 and 3 µM; Sigma, St Louis, MO, USA) 
and/or 4-phenylbutyric acid (PBA;1 and 3 mM; Sigma). For 5-Aza-2’-deoxycytidine treatment, 
cells were treated for 4 days and for histone acetylase inhibition, PBA was continuously 
administered by replacing the medium containing PBA every 24 hr for 5 days. 5-Aza-2’-
deoxycytidine with PBA treatment, 5-Aza-2’-deoxycytidine was removed after 48 hrs, while PBA 
was continuously administered every 24 hr for 5 days.  
 
miRNA and mRNA expression analysis  
miRNA expression analysis was performed as previously described 25. In brief, cDNA was 
synthesized from total RNA using gene-specific primers according to the TaqMan MicroRNA 
Assay protocol (Applied Biosystems, Inc., Foster City, CA, USA). Real-time PCR was performed 
using an Applied Biosystems 7300 Sequence Detection system. The 10 µl PCR included 0.67 µl 
RT product, 1x TaqMan Universal PCR master mix and 1 µl of primers and probe mix of the 
TaqMan MicroRNA Assay protocol (Applied Biosystems, Inc.). Expression was normalized 
using TaqMan microRNA endogenous control assay RNAU6B. 
 
DNA methylation analyses  
We searched the human genome database (http://genome.ucsc.edu/) (University of California 
Santa Cruz, Genome Bioinformatics) for the existence of miRNAs embedded in a CpG island. 
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Genomic DNA samples were modified by sodium bisulfite using the CpGenome DNA 
modification kit (Chemicon, Temecula, CA, USA) following the manufacturer’s instructions.  
 
The DNA methylation status was analyzed by methylation specific PCR (MSP) after sodium 
bisulfite modification of DNA. Human male genomic DNA universally methylated for all genes 
(Intergen Company, Purchase, NY) was used as a positive control for methylated alleles. Water 
blanks were included with each assay. Primer sequences of MSP of each miRNA are described 
in Supplementary Table S1. Following amplification, PCR products were subjected to gel 
electrophoresis through a 2.5% agarose gel and were visualized by ethidium bromide staining 
and UV transillumination. The second analysis was realized by bisulfite genomic sequencing 
(BSP) of both strands of the corresponding CpG islands. Following sodium bisulfite treatment, 
the 5’ region of miRNAs was PCR amplified. PCR products were subcloned using the One 
Shot® TOP10 kit (Invitrogen) into pCR® 4-TOPO® plasmid and candidate plasmid clones were 
sequenced. Primer sequences are described in Supplementary Table S1.  
 
Q-CHIP assay  
Colon carcinoma cell lines CACO2 and SW620 before and after treatment with the histone 
deacetylase inhibitor 4-phenylbutyric acid (PBA) were subjected to chromatin 
immunoprecipitation. The ChIP assays were performed as previously described 23 and the ChIP 
fractions were used for quantitative-PCR assay. Quantitative-PCR assay was performed in 
order to assess the acetylated Histone 3 (AcH3: Upstate Biotechnologies, Lake Placid, NY) 
modification. Immunoprecipitated DNA fractions (10 ng) from antibody-bound and input 
chromatin were analyzed by real-time PCR using SYBR Green detection and the LightCycler 
platform. The amplification of the immunoprecipitation fraction (IP) was used as a target 
sequence and input DNA (In) as reference sequence. Both fractions were amplified in the same 
run and following the same procedure of Q-PCR-Chip. The specific primers used for the Q-
CHIP are described in Supplementary Table S1. The following program conditions were applied 
for Q-PCR-Chip running: denaturation program, consisting in one cycle at 95oC for 10 minutes; 
amplification program, consisting in 45 cycles at 95oC for 10 s, 60oC for 10 s and 72oC for 10 s; 
melting program, one cycle at 95oC for 0 s, 40oC for 60 s and 90oC for 0 s; and cooling program, 
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one cycle at 40oC for 60s. The temperature transition rate was 20oC/s, except for the melting 
program, which was 0.2oC/s between 40oC and 90oC. A procedure based on the relative 
quantification of target sequence (IP) vs. their controls/calibrators in relation to the reference 
sequence (In) was used to assess the level of AcH3. Calculations were automatic performed by 
LightCycler software (RealQuant, version 1.0, Roche). The normalized ratio was obtained from 
the next equation and expressed as percentage of the control/calibrator: 
Normalised ratio (N) = (Etarget)∆Cp target (control – sample) ÷ (Eref)∆Cp ref (control – sample) 
Efficiencies (E) of each amplifications were calculated from the slopes of crossover points (Cp) 
vs DNA concentration plot, according to the formula E = 10(-1/slope). ∆Cp corresponded to the 
difference between control/calibrator Cp and sample Cp, either for the target or for the reference 
sequences. The level of AcH3 was determined relative to input chromatin of each sample. 
 
Statistical Analysis 
Correlations between methylation state and clinico-pathological features were assessed using 
χ
2
 or Fisher´s Exact probability tests as appropriate. All p-values presented are two-sided. A p-
value < 0.05 was regarded as statistically significant. All statistical tests were performed using 
the SPSS software package (version 15, SPSS, Chicago, IL).  
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RESULTS  
Identification of epigenetically regulated miRNAs in human colorectal cancer 
We have previously identified 23 miRNAs down-regulated in primary CRC in comparison with 
matched normal colorectal epithelial tissues 22. In order to determine whether these microRNAs 
could be epigenetically regulated we first examined their location in the genome. Out of the 23 
microRNAs down-regulated in CRC, 5 of them (hsa-miR-9, hsa-miR-124, hsa-miR-129, hsa-
miR-137, hsa-miR-149) were included within 1000bp of a CpG island. Since it has been 
predicted that >90% of the human miRNAs promoter are located 1000 bp upstream of the 
mature miRNA we decided to analyze the methylation status of these microRNAs 26. In order to 
do so, 3 CRC cell lines were treated with 5-Aza-2’-deoxycytidine and/or PBA followed by the 
analysis of miRNAs expression. While expression of hsa-miR-9 and hsa-miR-137 was up-
regulated after treatment with 5-Aza-2’-deoxycytidine or PBA, the effect was more pronounced 
when both 5-Aza-2’-deoxycytidine and PBA were combined. Furthermore, expression of hsa-
miR-129 was mostly up-regulated when both a demethylating agent and an inhibitor of histone 
deacetylases were used. Expression changes showed some variation according to the cell line 
employed (Figure 1A, 1B and 1C). Changes in the expression of the cell-cycle inhibitor 
p16/CDKN2A gene (data not shown) and the hsa-miR-127 were used as positive control of 
genes regulated by epigenetic inactivation as both genes have been previously demonstrated to 
be regulated epigenetically (Figure 1A, 1B and 1C) 20. These results indicate that hsa-miR-9, 
hsa-miR-129 and hsa-miR-137 could be regulated by aberrant DNA methylation and histone 
modification in CRC. 
 
Analysis of miRNAs promoter hypermethylation in CRC  
We next examined the methylation of the promoter regions of hsa-miR-9, hsa-miR-129 and hsa-
miR-137 by MSP to determine whether aberrant hypermethylation is responsible for silencing of 
miRNAs expression. Hsa-miR-9 is represented by three genomic loci hsa-miR-9-1 (1q22), hsa-
miR-9-2 (5q14.3), hsa-miR-9-3 (15q26.1). While hsa-miR-9-1 is located at 183bp of a CpG 
island and hsa-miR-9-3 is embedded in a CpG island, hsa-miR-9-2 is located more than 1000pb 
of a CpG island. Hsa-miR-129 is represented by two genomic loci but only one of them, hsa-
miR-129-2 at region 11p11.2, is embedded in a CpG island. On the contrary, hsa-miR-137 is 
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represented by one single locus located in 1p21.3 chromosome region which is inside on a CpG 
island. As shown in figure 2, all 4 microRNAs (hsa-miR-9-1, hsa-miR-9-3, hsa-miR-129-2 and 
hsa-miR-137) were found to be hypermethylated in Caco2 and LS513 CRC cell lines and 
methylation  was partially reverted by treatment with 5-Aza-2’-deoxycytidine (Figure 2A). MSP 
analysis of hsa-miR-9-1, hsa-miR-9-3, has-miR-129-2 and hsa-miR-137 loci in a panel of 7 CRC 
cell lines revealed that the hsa-miR-129-2 and hsa-miR-137 were un-methylated in the LS174 
cell line (Figure 2B) while the rest of cell lines showed methylation of at least one allele. 
Expression of the mature hsa-miR-129 and hsa-miR-137 were not detected in either of 
methylated CRC cell lines (data not shown). Interestingly, MSP analysis of hsa-miR-137 
revealed a dramatic size difference in the PCR products among the different cell lines 
consistent with the presence of heterozygous VNTR alleles in RKO and LS174 cell lines (Figure 
2B). A variable number of tandem repeats (VNTR) 5' to the pre-miR-137 has been previously 
identified 27. The design of the primers for the MSP analysis used a reference DNA sequence 
that included three repeats (VNTR) of 15 bases (GenBank no. AK094607). While the Caco2 cell 
lines contained 6 copies of the 15 base-repetition VNTR (TAGTAGCGGTAGCGG) only 3 copies 
were detected in the LS513 cell line. Sequencing analysis of this region showed that the VNTR 
copy number affect the number of CpG dinucleotides that can modify the chromatin structure 
(Supplementary Figure S1).  
 
Methylation of hsa-miR-9-1 and hsa-miR-9-3 loci and expression of hsa-miR-9 showed a 
heterogenous behavior (Figure 2B). Low-expression of the mature miRNA (hsa-miR-9) was 
correlated mainly with methylation of hsa-miR-9-1, but not with methylation of the hsa-miR-9-3 
as indicated by the fact that the hsa-miR-9-3 locus was found methylated on HCT116 and 
SW620 cell lines that showed high hsa-miR-9 expression (Figure 2B and Figure 2C).  
MSP results obtained for hsa-miR-9-1 and hsa-miR-9-3 were confirmed by bisulphite 
sequencing (Figure 3A and 3B). 
 
Regulation of microRNA expression by histone 3 acetylation  
The fact that expression of microRNAs was upregulated by the combined treatment with 5-Aza-
2’-deoxycytidine and PBA suggested that histone acetylation could also be involved in the 
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regulation of microRNA expression. CRC cell lines were subjected to chromatin 
immunoprecipitation with an antibody against acetylated H3 (a mark of transcriptional active 
chromatin) followed by Q-PCR for hsa-miR-9-1, hsa-miR-9-3, hsa-miR-129 and hsa-miR-137 
before and after treatment with PBA. Treatment of Caco2 and SW620 cells with PBA induced 
an increase in the AcH3 in the case of hsa-miR-9-3 and hsa-miR-127. However, we could only 
detected slight changes of AcH3 by quantitative CHIP assay when we examined hsa-miR-129-
2, hsa-miR-9-1 and hsa-miR-137. These results in addition to the expression analysis shown in 
figure 1 indicate that expression of the mature hsa-miR-9 could be regulated by 
hypermethylation of the hsa-miR-9-1 locus and H3 de-acetylation of the hsa-miR-9-3 locus at 
least in Caco2 cells (Figure 4).  
 
Methylation analysis of hsa-miR-9-1, hsa-miR-129 and hsa-miR-137 in primary CRC 
tissues 
Finally, we analyzed the methylation status of hsa-miR-9-1, hsa-miR-129-2 and hsa-miR-137 in 
a group of matched samples of primary CRC samples and adjacent normal tissue. Tumor-
specific DNA methylation of hsa-miR-9-1, hsa-miR-129-2 and hsa-miR-137 was detected in 56% 
(20 of 36), 91% (31 of 34) and 100% (31 of 31) of primary CRC cases analyzed, respectively. 
Representative examples are shown in Figure 5. Hsa-miR-9-1 was completely unmethylated in 
samples of normal colonic tissue. Interestingly, we found methylation of hsa-miR-129-2 and hsa-
miR-137 in 12% (4 of 34) and 23% (7 of 31) in histologically normal colorectal mucosa from 
individuals with colorectal cancer. These results suggest the possibility of a colorectal mucosal 
'field defect' related to aberrant microRNA-methylation. 
 
Similar to CRC cell lines, hsa-miR-129-2 and hsa-miR-137 hypermethylation was found in 
almost every sample analyzed and these alterations did not correlate any of the clinico-
pathological features of primary CRC. However, when we evaluated the correlation between 
hsa-miR-9-1 methylation and clinico-pathological features of primary CRC we observed that  
methylation was more frequent in advanced stages of CRC and was associated with regional 
nodal invasion (p=0.008), vascular invasion (p=0.004) and metastasis (p=0.016) (Table 1). 
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These results suggest that hsa-miR-9-1 silencing could have a role in the malignant progression 
of colorectal cancer.  
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DISCUSSION 
In the current study we have shown the first demonstration that suppression of hsa-miR-9, hsa-
miR-129 and hsa-miR-137 genes in colorectal cancer is mediated at least in part by epigenetic 
mechanisms including DNA hypermethylation and histone acetylation. Moreover, the frequent 
hypermethylation of these miRNA genes in CRC and the correlation between methylation and 
clinico-pathological supports the concept that epigenetic instability is an important event in 
human tumorigenesis specifically in colorectal carcinoma.  
 
Epigenetic regulation of miRNAs mediated by inadequate methylation has been previously 
described. Saito et al 14 provided the first evidence for the involvement of DNA methylation in 
the regulation of miRNA expression in carcinoma cells identifying 17 miRNA up-regulated in 
bladder cancer cells after treatment with 5-Aza and PBA. However, no changes in miRNA 
expression were detected after treatment with 5-Aza or PBA alone suggesting that epigenetic 
control of miRNA expression includes DNA methylation and histone modifications at least in 
their model. Other report 21 suggested that treatment of a breast cancer cell line with a 
proapoptotic dose of the HDAC inhibitor hydroxamic acid LAQ824 resulted in both up-regulation 
and down regulation of several miRNA transcripts supporting a role of epigenetic mechanism in 
the regulation of microRNA expression. On the other hand, Diederichs et al 28 showed that 
miRNA expression are not induced by demethylating agents or HDAC inhibitors in the lung 
cancer cell line A549. This discrepancy may reflect different responses in the cell lines tested as 
well as dose-dependent effects of the different HDAC inhibitors. Our results confirm previous 
studies, suggesting that aberrant alteration in DNA methylation and histone modification 
suppress miRNA expression in colorectal cancer.  
 
The differences between methylation of hsa-miR-9-1, hsa-miR-129 and hsa-miR-137 in primary 
CRC tumors and normal mucosa suggest that similar to classic tumor-supressor genes, DNA 
methylation could be an important molecular mechanism for the down-regulation of miRNA 
expression. Moreover, the association between hsa-miR-9-1 methylation and more advanced 
stages and nodal involvement supports a role for hsa-miR-9-1 methylation as a potential tumor 
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marker of poor outcome in colorectal cancer. However, further investigation would be required 
to study the involvement of hsa-miR-9-1 in distant metastasis and patient survival. 
 
Other miRNAs has been shown to be hypermethylated in CRC. Methylation of the hsa-miR-
34b/c CpG island was frequently observed in CRC cell lines and in primary CRC tumors, but not 
in normal colonic mucosa suggesting a tumor-specific methylation 29. Moroever, Grady et al 30 
showed that the EVL/hsa-hsa-miR-342 locus was methylated in 86% of colorectal 
adenocarcinomas and in 67% of adenomas, indicating that it is an early event in colorectal 
carcinogenesis. In addition, similar to our results with hsa-miR-137 they observed a high 
frequency of methylation (56%) in histologically normal colorectal mucosa from individuals with 
concurrent cancer, suggesting the existence of a 'field defect' involving miRNAs.  
The precise function of hsa-miR-9, hsa-miR-129, and hsa-miR-137 have not been characterized 
although abnormal expression has been described in tumor samples. Hsa-miR-9 has been 
described as a putative tumor suppressor gene in recurrent ovarian cancer 31 and genome-wide 
profiling of methylated promoters identified hsa-miR-9-1 as a miRNA frequently 
hypermethylated in pancreatic adenocarcinoma 32. Lehmann et al 33 showed differential 
methylation of hsa-miR-9-1 in a large series of primary human breast cancer specimens. In 
agreement with our results a good correlation between hypermethylation of the hsa-miR-9-1 
gene and down-regulation of expression in tumour tissue was found. On the other hand, Kozaki 
et al 34 identified hsa-miR-137 as a tumor suppressor miRNA frequently silenced by DNA 
methylation in oral squamous cell carcinoma which was implicated  in the regulation of cell 
growth mediated by regulation of cyclin-dependent kinase 6 (CDK6) . Expression of hsa-miR-
137 was also significantly down-regulated in glioblastoma multiforme cells and over–expression 
of microRNA-137 induced differentiation of brain tumor stem cells 35. The presence of a 15-bp 
VNTR in the primary miRNA of hsa-miR-137 detected in CRC cell lines may affect directly gene 
methylation since the number of CpGs differs according to the VNTR copy number. Bemis et al 
27
 have already described the presence of this VNTR in melanoma cell lines and showed that 
alterations in the number of tandem repeats in this area interfere with mature hsa-miR-137 
processing and function. In this sense, it has been postulated that local sequence features can 
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contribute to the susceptibility of a CpG island to become methylated or to be protected from 
methylation 36 
 
In summary, our study shows that miRNA-specific hypermethylation in CRC and histone-
deacetylation could be an important molecular mechanism causing the global down-regulation 
of miRNAs. Considering the high frequency of miRNA hypermethylation found in CRC cancer, 
miRNA gene methylation could be considered as useful tumor marker. 
Page 14 of 25
John Wiley & Sons, Inc.
International Journal of Cancer
 15
Acknowledgment: 
We thank Ines Lopez and Marisol Gonzalez for their excellent technical assistance. 
Natalia Ramirez is supported by the Fundación Científica de la Asociación Española contra el 
Cáncer. 
Page 15 of 25
John Wiley & Sons, Inc.
International Journal of Cancer
 16
REFERENCES 
 1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-
97. 
 2. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 
2004;5:522-31. 
 3. Ambros V. The functions of animal microRNAs. Nature 2004;431:350-5. 
 4. Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet 
Dev 2005;15:563-8. 
 5. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs 
modulate E2F1 expression. Nature 2005;435:839-43. 
 6. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert 
KL, Brown D, Slack FJ. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-47. 
 7. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 
2006;6:259-69. 
 8. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto 
A, Yokota J, Tanaka T, Calin GA, Liu CG, et al. Unique microRNA molecular profiles in lung cancer 
diagnosis and prognosis. Cancer Cell 2006;9:189-98. 
 9. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA, Jr., Sjoblom T, Barad O, Bentwich Z, 
Szafranska AE, Labourier E, Raymond CK, Roberts BS, et al. The colorectal microRNAome. Proc Natl 
Acad Sci U S A 2006;103:3687-92. 
 10. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, 
Ferracin M, Prueitt RL, Yanaihara N, et al. A microRNA expression signature of human solid tumors 
defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61. 
 11. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, 
Mak RH, Ferrando AA, Downing JR, Jacks T, et al. MicroRNA expression profiles classify human 
cancers. Nature 2005;435:834-8. 
 12. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J. 
Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008;451:147-52. 
 13. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon 
D, Jackson AL, Linsley PS, et al. A microRNA component of the p53 tumour suppressor network. Nature 
2007;447:1130-4. 
 14. Saito Y, Jones PA. Epigenetic Activation of Tumor Suppressor MicroRNAs in Human 
Cancer Cells. Cell Cycle 2006;5:2220-2. 
 15. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan 
S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and 
genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004. 
 16. Deng S, Calin GA, Croce CM, Coukos G, Zhang L. Mechanisms of microRNA deregulation 
in human cancer. Cell Cycle 2008;7:2643-6. 
 17. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 
2007;16 Spec No 1:R50-9. 
 18. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a 
brighter future. Oncogene 2002;21:5427-40. 
 19. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant 
patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 
2001;10:687-92. 
 20. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA. Specific 
activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying 
drugs in human cancer cells. Cancer Cell 2006;9:435-43. 
 21. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels 
by histone deacetylase inhibition. Cancer Res 2006;66:1277-81. 
 22. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, Abajo A, Navarro A, 
Moreno I, Monzo M, Garcia-Foncillas J. Identification by Real-time PCR of 13 mature microRNAs 
differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006;5:29. 
 23. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, Casado S, Suarez-
Gauthier A, Sanchez-Cespedes M, Git A, Spiteri I, Das PP, et al. Genetic unmasking of an epigenetically 
silenced microRNA in human cancer cells. Cancer Res 2007;67:1424-9. 
 24. Han L, Witmer PD, Casey E, Valle D, Sukumar S. DNA Methylation Regulates MicroRNA 
Expression. Cancer Biol Ther 2007;6. 
Page 16 of 25
John Wiley & Sons, Inc.
International Journal of Cancer
 17
 25. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, 
Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, et al. Real-time quantification of microRNAs by 
stem-loop RT-PCR. Nucleic Acids Res 2005;33:e179. 
 26. Zhou X, Ruan J, Wang G, Zhang W. Characterization and identification of microRNA core 
promoters in four model species. PLoS Comput Biol 2007;3:e37. 
 27. Bemis LT, Chen R, Amato CM, Classen EH, Robinson SE, Coffey DG, Erickson PF, 
Shellman YG, Robinson WA. MicroRNA-137 targets microphthalmia-associated transcription factor in 
melanoma cell lines. Cancer Res 2008;68:1362-8. 
 28. Diederichs S, Haber DA. Sequence variations of microRNAs in human cancer: alterations in 
predicted secondary structure do not affect processing. Cancer Res 2006;66:6097-104. 
 29. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, Tokino T. Epigenetic 
silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation 
in colorectal cancer. Cancer Res 2008;68:4123-32. 
 30. Grady WM, Parkin RK, Mitchell PS, Lee JH, Kim YH, Tsuchiya KD, Washington MK, 
Paraskeva C, Willson JK, Kaz AM, Kroh EM, Allen A, et al. Epigenetic silencing of the intronic 
microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 2008;27:3880-8. 
 31. Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, 
Gleeson N, D'Arcy T, McGuinness E, et al. Potential role of miR-9 and miR-223 in recurrent ovarian 
cancer. Mol Cancer 2008;7:35. 
 32. Omura N, Li CP, Li A, Hong SM, Walter K, Jimeno A, Hidalgo M, Goggins M. Genome-
wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther 2008;7. 
 33. Lehmann U, Hasemeier B, Christgen M, Muller M, Romermann D, Langer F, Kreipe H. 
Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 2007. 
 34. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive 
microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008;68:2094-105. 
 35. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger 
DG, James CD, Costello JF, Bergers G, Weiss WA, et al. miR-124 and miR-137 inhibit proliferation of 
glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008;6:14. 
 36. Ronneberg JA, Tost J, Solvang HK, Alnaes GI, Johansen FE, Brendeford EM, Yakhini Z, 
Gut IG, Lonning PE, Borresen-Dale AL, Gabrielsen OS, Kristensen VN. GSTP1 promoter haplotypes 
affect DNA methylation levels and promoter activity in breast carcinomas. Cancer Res 2008;68:5562-71. 
 
Page 17 of 25
John Wiley & Sons, Inc.
International Journal of Cancer
 18
FIGURE LEGENDS 
Figure 1: Expression of hsa-miR-9, hsa-miR-129, hsa-miR-137 and hsa-miR-127 is 
regulated epigenetically in CRC 
A) qRT-PCR analysis of the hsa-miR-9, hsa-miR-129, hsa-miR-137 and  hsa-miR-127 in CRC 
cell lines before and after treatment with 5-Aza-2’-deoxycytidine (AZA). B) qRT-PCR analysis of 
the hsa-miR-9, hsa-miR-129, hsa-miR-137 and hsa-miR-127 in CRC cell lines before and after 
treatment with 4-phenylbutyric acid (PBA) C) qRT-PCR analysis of the hsa-miR-9, hsa-miR-129, 
hsa-miR-137 and  hsa-miR-127 in CRC cell lines before and after treatment with 5-Aza-2’-
deoxycytidine and histone deacetylase inhibitor 4-phenylbutyric acid (PBA) . ddCT: is the value 
of the normalized expression of the miRNA (Ct miRNA-Ct RNU6B) in treated cell line minus 
normalized expression value of the miRNA in non-treated cell line. 
 
Figure 2: Methylation of hsa-miR-9-1, hsa-miR-9-3, hsa-miR129-2 and hsa-miR137 in CRC 
cell lines 
A) MSP analysis of the hsa-miR-9-1,hsa-miR9-3, hsa-miR129-2 and hsa-miR137 CpG island 
regions in Caco2 and LS513 CRC cells lines control and treated with 5-Aza-2’-deoxycytidine. B) 
MSP analysis of the hsa-miR-9-1,hsa-miR9-3, hsa-miR129-2 and hsa-miR137 CpG island 
regions in a panel of CRC cell lines. U: un-methylated , M: methylated . C+: methylated control. 
C) Expression analysis of mature hsa-miR-9 in CRC cell lines measured by qRT-PCR. Data are 
expressed as 2 -∆Ct values obtained by normalization using RNU6B as endogenous control.  
 
Figure 3: Bisulphite sequencing of hsa-miR-9-1 and hsa-miR-9-3. 
a) Bisulphite sequencing of the hsa-miR-9-1 CpG island region in positive methylated control (+ 
control) and CRC derived cell lines (control and treated with 5-Aza-2’-deoxycytidine). Each 
circle indicates a CpG dinucleotide (black circle: methylated CpG; open circle: unmethylated 
CpG). Eight clones were sequenced for each cell line.  
b) Bisulphite sequencing of the hsa-miR-9-3 CpG island region in positive methylated control (+ 
control) and CRC derived cell lines (control and treated with 5-Aza-2’-deoxycytidine ). Each box 
indicates a CpG dinucleotide (black circle: methylated CpG; open circle: unmethylated CpG). 
Eight clones were sequenced for each cell line.  
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Figure 4: Histone 3 acetylation analysis in  promoter region of the hsa-miR-127, hsa-miR-
9-1, hsa-miR-9-3, hsa-miR-129 and hsa-miR-137 genes in CRC cell lines before and after 
treatment with AZA and PBA. 
Quantitative-ChIP-PCR analysis for the acetylation of histone 3 in the hsa-miR-127, hsa-miR-9-
1, hsa-miR-9-3, hsa-miR-129 and hsa-miR-137 CpG islands. Values are expressed as the 
percentage of the acetylation of histone 3 mark in CRC derived CACO and SW620 cell lines 
after treatment with AZA+PBA in comparison with expression in these cell lines before 
treatment (100%). AZA: 5-Aza-2’-deoxycytidine; PBA: 4-phenylbutyric acid. 
 
Figure 5: Methylation analyses for hsa-miR-9-1, hsa-miR-129-2 and hsa-miR-137 CpG 
islands in primary colorectal tumors. 
MSP analysis for -miR-9-1, hsa-miR-129-2 and hsa-miR-137  in surgically resected primary 
colorectal tumors (T) and corresponding noncancerous colon mucosa (N). Unmethylated (U) or 
methylated (M) sequences. In vitro methylated DNA (IVD) is shown as methylated control 
sequences.  
 
Supplementary Figure 1: Sequencing analysis of the VNTR repeat region 
(TAGCAGCGGCAGCGG) in hsa-miR-137 from cell lines Caco2 and LS513. Six repeats are 
found in Caco2 and 3 repeats in LS513. 
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Table 1: Clinico-pathological characteristics of CRC patients according to hsa-miR-9-1 
methylation status. 
 
 
Feature  miR-9-1 Non Methylated (n=16) miR-9-1  Methylated (n=20) p-value 
Age     
  
<65 years 5 5 ns 
>65 years 11 15   
Sex 
      
M 11 12 ns 
F 5 8   
Localization 
      
proximal 4 6 ns 
distal 12 16   
Hystological grade 
      
well-differentiated 8 8 ns 
poor-differentiated 8 12   
Stage 
      
I+II 14 9 0.008 
III+IV 2 11   
Vascular invasion 
      
non 16 12 0.004 
yes 0 8   
lymph-node involvement 
      
non 14 9 0.008 
yes 2 11   
Metastasis 
      
non 16 14 0.016 
yes 0 6   
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